Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262886 · ClinicalTrials.gov registry record · Phase 2
Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00262886 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 35 participants.
The verdict
NCT00262886, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: A peripheral stem cell transplant or bone marrow transplant from a brother or sister may be an effective treatment for kidney cancer. PURPOSE: This phase II trial is studying how well a donor peripheral stem cell or bone marrow transplant works in treating patients with relapsed or refractory metastatic kidney cancer.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL therapeutic allogeneic lymphocytes
- BIOLOGICAL graft-versus-tumor induction therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262886
The ClinicalTrials.gov registry entry for NCT00262886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00262886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00262886 about?
NCT00262886 is a clinical study titled "Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer". RATIONALE: A peripheral stem cell transplant or bone marrow transplant from a brother or sister may be an effective treatment for kidney cancer. PURPOSE: This phase II trial is studying how well a donor peripheral stem cell or bone marrow transplant works in treating patients with relapsed or refra...
What is the current status of trial NCT00262886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2001-08.
What interventions are being tested in trial NCT00262886?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), anti-thymocyte globulin (BIOLOGICAL), therapeutic allogeneic lymphocytes (BIOLOGICAL), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00262886?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.